Publications by the researcher in collaboration with Ana Estany Gestal (10)

2024

  1. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

    Diseases, Vol. 12, Núm. 10

  2. Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

    Pharmaceuticals, Vol. 17, Núm. 2

  3. The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration

    Pharmaceutics, Vol. 16, Núm. 1

2023

  1. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  2. Efficacy and Safety of Inhaled Ethanol in Early-Stage SARS-CoV-2 Infection in Older Adults: A Phase II Randomized Clinical Trial

    Pharmaceutics, Vol. 15, Núm. 2

  3. Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

    Investigative ophthalmology & visual science, Vol. 64, Núm. 13, pp. 34

2022

  1. Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial

    European Respiratory Journal, Vol. 60, Núm. 2

  2. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

2021

  1. Estudio observacional, multicéntrico y prospectivo para evaluar los cambios en la función cognitiva en pacientes tratados con iPCSK9. Protocolo de estudio

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 3, pp. 150-154

2020

  1. First-Days Reduction of Plasma and Skin Advanced Glycation End Products is Related to Outcome in Septic Patients

    Shock, Vol. 53, Núm. 4, pp. 400-406